Company intelligence / Profile preview

Cuyahoga

Cleveland, Ohio, United States

Ownership: Private
Development stage: Other

Overview

Cuyahoga Oncology is a pre-clinical stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of cancer. The company's primary research centers on targeting protein tyrosine phosphatases, specifically PTP1B and TCPTP, which play critical roles in immune evasion and tumor growth. By inhibiting these enzymes, Cuyahoga aims to enhance the body's natural immune response against various solid tumors. The company was founded based on research from Case Western Reserve University and is part of the growing life sciences ecosystem in Cleveland, Ohio.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Cuyahoga.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cuyahoga.

Explore the full profile